gettyimages.com
May 10, 2025, 10:10
Thaís Baccili Cury Megid Shares Meta-Analysis Supporting DFS as Surrogate for OS in Pancreatic Cancer
Thaís Baccili Cury Megid, Medical Oncologist at Vitalité Health Network, posted on LinkedIn:
“I am proud to have collaborated with amazing team in this relevant study. Thank you Luis Felipe Leite da Silva for the invite.
Disease-free survival (DFS) has been used as an alternative to overall survival (OS) in trials of early-stage pancreatic cancer, but prior evidence on its reliability as a surrogate endpoint has been mixed.
In this meta-analysis of 29 randomised trials (6777 patients), DFS demonstrated a strong trial-level correlation with OS (R=0.70 in adjuvant and R=0.90 in neoadjuvant settings).
Treatment effects on DFS had a strong correlation with treatment effects on OS, making DFS a potential surrogate endpoint for OS in early-stage PC trials.”
Title: Disease-free survival as a surrogate for overall survival in early-stage pancreatic cancer trials: a correlation meta-analysis.
Authors: Luís Felipe Leite, Luiz F Costa de Almeida, Lucas Diniz da Conceição, Mariana Macambira Noronha, Marcos Belotto, Erick F Saldanha, Thais Baccili Cury Megid, Renata D’Alpino Peixoto, Bishal Gyawali
Read The Full Article at BMJ Oncology.
More posts featuring Pancreatic Cancer.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
May 10, 2025, 14:14
May 10, 2025, 14:11
May 10, 2025, 13:57